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Summary
Gastric is considered neglected cancer in terms of stage at diagnosis and success of treatment worldwide. Early detec-
tion and quality of gastric cancer surgery remain the most important for successful treatment in terms of overall survival. In 
this paper, we focus on the overview of hospitals and volume of gastric cancer in Croatia as a possible baseline for quality 
assessment and implementation of existing quality guidelines. We accessed publicly available data from the Croatian Insur-
ance Fund for the period between 1st January 2013 to 31st December 2018. For background information on gastric cancer 
incidence and mortality, we used Croatian Cancer Registry data available online. We obtained both the number of resected 
gastric cancer in all Croatian hospitals as well as the length of stay. Data analysis discovered that there is a clear volume 
difference between teaching hospitals and non-teaching hospitals; only the first have sufficient volume for quality audit. 
This overview stresses one of the most critical points in cancer surgery, volume of surgery as a quality indicator.
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PREGLED KIRURŠKOG LIJEČENJA RAKA ŽELUCA PREMA BROJU OPERACIJA  
U POJEDINIM BOLNICAMA U HRVATSKOJ
Sažetak
Rak želuca smatra se zanemarenim tumorom zbog kasne dijagnoze i ishoda liječenja. Rano otkrivanje i kvaliteta ope-
racijskog liječenja najvažniji su za uspješno liječenje i ukupno preživljenje. U radu predstavljamo pregled bolnica i broj 
operiranih bolesnika s rakom želuca u Hrvatskoj kao moguću osnovu za ocjenu i provedbu postojećih smjernica kvalitete. 
Korišteni su javno dostupni podatci Hrvatskog zavoda za zdravstveno osiguranje od 1. siječnja 2013. do 31. prosinca 2018. 
Podatci o učestalosti i smrtnosti od raka želuca su sa internetskih stranica Hrvatskog registra za rak pri Hrvatskom zavodu 
za javno zdravstvo. Prikazan je broj operiranih od raka želuca i duljina boravka u svim hrvatskim bolnicama. Ustanovljena 
je jasna razlika u broju operiranih bolesnika s rakom želuca između nastavnih i nenastavnih bolnica. Samo nastavne imaju 
dovoljan broj za reviziju kvalitete. Broj operacija je najvažnija mjera kvalitete u onkološkoj kirurgiji.




Gastric is considered neglected cancer in terms 
of stage at diagnosis and success of treatment 
worldwide, with Japan and Korea being the ex-
ceptions (1). The trend of falling incidence is re-
corded in developed countries mostly attributed 
to Helicobacter pylori eradication (2).
Unlike most European Union countries, both 
the incidence and mortality in Croatia are rather 
stable (3,4). Late diagnosis and poor patient gen-
eral condition is something we are forced to han-
dle and have addressed in our previous paper on 
cachexia and preconditioning being quintessential 
for undergoing possible curative treatment or at 
least being a candidate for neoadjuvant treatment 
or palliative resection/bypass (5).
However, early detection and quality of gas-
tric cancer surgery remain most important for suc-
cessful treatment in terms of overall survival. In 
this paper, we focus on the overview of hospitals 
and volume of gastric cancer in Croatia as a pos-
sible baseline for quality assessment and imple-
mentation of existing quality guidelines.
MATERIALS AND METHODS
For this overview, we accessed publicly avail-
able data from the Croatian Insurance Fund (7) for 
the period between 1st January 2013 to 31st of De-
cember 2018. For background information on gas-
tric cancer incidence and mortality, we used Croa-
tian Cancer Registry data available online (8).
We searched for the number of resected gas-
tric cancer in all Croatian hospitals through DTS 
system for reimbursement and recorded all subto-
tal, distal, total and radical gastrectomies for C16 
diagnoses and the center they pertained to. We 
also recorded the length of stay.
Hospitals in Croatia are classified by the 
number of teaching units with defined equipment 






and personnel which are then financed by State 
and most non-teaching hospitals that are funded 
by counties or towns.
RESULTS
In the period between 2013 and 2018, the 
number of gastrectomies per institution is rather 
stable. The overall number of surgical resection 
for gastric cancer fell for about 20% during the pe-
riod.
The non-teaching hospitals number of cases 
is well bellow the recommended volume per hos-
pital, while the teaching hospitals have a sufficient 
number of cases.
The hospital length is on average 10 days lon-
ger in local hospitals (Figure 4).
DISCUSSION
Gastric cancer has a stable incidence and 
mortality in Croatia whit about 900 cases annually 
and overall survival of 20% for five year period 
(3,9). Data on stage at diagnosis confirms the late 
stages of onset and limited treatment options. 
However, over half of the cases get potentially cu-
rative surgical treatment.
Based on ESSO guidelines for quality of sur-
gery we wanted to evaluate the landscape of gas-
tric cancer surgery volume in Croatia as one of the 
basic quality indicators (10,11). There is a clear 
volume difference between teaching hospitals and 
non-teaching hospitals, only first have sufficient 
volume for quality audit.
The length of hospital stay in this overview is 
on average ten days longer for local hospitals ver-
sus teaching hospitals. Longer hospital stay cor-
relates with higher real treatment costs. This is dif-
ficult to trace as Croatian Insurance fund reim-
burses expenses per group of diagnosis.
The bias of this overview is correct reporting 
of procedures, which we tried to recheck (elimi-
nate) by checking the number of procedures at our 
institution through our data registries and the ad-
justment was needed for one year only (*in the 
Figure 3).
For a precise analysis of treatment and out-
comes, it would be ideal to look at clinical path-
ways, however, we did not have sufficient logis-
tics for that approach. Nevertheless, this overview 
stresses one of the most important points in cancer 
surgery volume of surgery as a quality indicator.
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